Literature DB >> 9153452

Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation.

C E Thomas1, S A Mayer, Y Gungor, R Swarup, E A Webster, I Chang, T H Brannagan, M E Fink, L P Rowland.   

Abstract

We retrospectively reviewed the hospital records of 53 patients admitted for 73 episodes of myasthenic crisis at Columbia-Presbyterian Medical Center over a period of 12 years, from 1983 to 1994. Median age at the onset of first crisis was 55 (range, 20 to 82), the ratio of women to men was 2:1, and the median interval from onset of symptoms to first crisis was 8 months. Infection (usually pneumonia or upper respiratory infection) was the most common precipitating factor (38%), followed by no obvious cause (30%) and aspiration (10%). Twenty-five percent of patients were extubated at 7 days, 50% at 13 days, and 75% at 31 days; the longest crisis exceeded 5 months. Using survival analysis and backward stepwise Cox regression, we identified three independent predictors of prolonged intubation: (1) pre-intubation serum bicarbonate > or = 30 mg/dl (p = 0.0004, relative hazard 4.5), (2) peak vital capacity day 1 to 6 post-intubation < 25 ml/kg (p = 0.001, relative hazard 2.9), and (3) age > 50 (p = 0.01, relative hazard 2.4). The proportion of patients intubated longer than 2 weeks was 0% among those with no risk factors, 21% with one risk factor, 46% with two risk factors, and 88% with three risk factors (p = 0.0004). Complications independently associated with prolonged intubation included atelectasis (p = 0.002), anemia treated with transfusion (p = 0.03), Clostridium difficile infection (p = 0.01), and congestive heart failure (p = 0.03). Three episodes of crisis were fatal, for a mortality rate of 4% (3/73); four additional patients died after extubation. All seven deaths were due to overwhelming medical comorbidity. Over half of those who survived were functionally dependent (home or institutionalized) at discharge. In addition to prospective controlled studies of immunotherapies, the prevention and treatment of medical complications offers the best opportunity for further improving the outcome of myasthenic crisis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153452     DOI: 10.1212/wnl.48.5.1253

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  65 in total

1.  Psychosocial aspects in myasthenic patients treated by plasmapheresis.

Authors:  Yu-Tai Chen; Yuanmay Chang; Hou-Chang Chiu; Jiann-Horng Yeh
Journal:  J Neurol       Date:  2011-02-02       Impact factor: 4.849

Review 2.  Myasthenic crisis.

Authors:  David Lacomis
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

3.  Risk of extubation failure in patients with myasthenic crisis.

Authors:  Alejandro A Rabinstein; Nils Mueller-Kronast
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

4.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

Review 5.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

Review 6.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

7.  Clostridium difficile-associated disease acquired in the neurocritical care unit.

Authors:  S A Musa; H Robertshaw; S J Thomson; M L Cowan; T M Rahman
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

8.  The role of non-invasive ventilation and factors predicting extubation outcome in myasthenic crisis.

Authors:  Jenn-Yu Wu; Ping-Hung Kuo; Pi-Chuan Fan; Huey-Dong Wu; Fuh-Yuan Shih; Pan-Chyr Yang
Journal:  Neurocrit Care       Date:  2008-09-20       Impact factor: 3.210

9.  Myasthenic Crisis.

Authors:  Jawad F. Kirmani; Abutaher M. Yahia; Adnan I. Qureshi
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

Review 10.  History of Myasthenia Gravis Revisited.

Authors:  Feza Deymeer
Journal:  Noro Psikiyatr Ars       Date:  2020-11-07       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.